Keyword → VRTX

Vertex Pharmaceuticals Acquires Crinetics for $85 Per Share — $10B All-Cash Deal Targets $5B+ Endocrinology Peak Sales

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $85 per share in an all-cash deal valued at approximately $10 billion, a 102% premium to Crinetics' Monday close. The deal, unanimously approved by both boards, adds PALSONIFY, the first approved once-daily oral acromegaly therapy, and late-stage atumelnant for congenital adrenal hyperplasia, with management targeting more than $5 billion in combined peak annual revenue. The transaction is expected to close in Q3 2026.

FDA's Vinay Prasad to Exit Biologics Post in April, Sending Biotech Stocks Sharply Higher

The announced departure of Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, triggered a significant rally in biotech equities Monday, with uniQure surging more than 31% in premarket trading. Investors interpreted the news as a signal that the agency may adopt a more predictable and industry-friendly regulatory posture for vaccines, gene therapies, and rare disease treatments.

Gilead Sciences to Acquire Arcellx for $7.8 Billion in Major CAR-T Cell Therapy Bet

Gilead Sciences announced Monday it will acquire Arcellx for $115 per share in cash plus a contingent value right of $5 per share, representing an implied equity value of $7.8 billion and an 87% premium to Arcellx's Friday closing price. The deal centers on anito-cel, an investigational BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma that has already received FDA acceptance of its Biologics License Application, with a regulatory decision expected by December 23, 2026.

OPKO Health Schedules Q4 Earnings Report, Shares React to Upcoming Guidance

OPKO Health announced plans to release its fourth-quarter and full-year 2025 financial results later this month, expected to include commentary on future revenue and profitability. The upcoming earnings call could influence sentiment among healthcare and biotech investors amid broader market volatility.

Market Focus Shifts to Jobs, Inflation and Retail Data as Earnings Calendar Warms

Investors are bracing for a key week of economic data and corporate earnings, with delayed January jobs numbers, CPI inflation, and December retail sales due for release. Major technology and consumer firms are also reporting results, highlighting the intersection of macro indicators and corporate performance. These releases are expected to shape expectations for monetary policy and market direction in coming weeks.